References

rpmj

Research'n Practical Medicine Journal

Research and Practical Medicine Journal

2410-1893

"QUASAR", LLC

10.17709/2409-2231-2021-8-2-10

rpmj-727

Research Article

Обзор

Review

Возможности сочетания иммунотерапии с лучевой терапией в лечении больных неоперабельным местно-распространенным немелкоклеточным раком легкого

The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer

https://orcid.org/0000-0003-3782-7338

Смоленов

Е. И.

Smolenov

E. I.

Смоленов Евгений Игоревич – к.м.н., научный сотрудник отделения лучевого и хирургического лечения заболеваний торакальной области, SPIN: 6376-2673, AuthorID: 808954

249036, г. Обнинск, ул. Королева, д. 4

Evgeny I. Smolenov – Cand. Sci. (Med.), researcher of the department of radiation and surgical treatment of thoracic region diseases, SPIN: 6376-2673, AuthorID: 808954

4 Korolev str., Obninsk 249036

e.smolenov@gmail.com

https://orcid.org/0000-0002-7128-2397

Афонин

Г. В.

Afonin

G. V.

Афонин Григорий Владиславович – к.м.н., старший научный сотрудник отделения лучевого и хирургического лечения заболеваний торакальной области, SPIN: 9039-6110, AuthorID: 896307, ResearcherID: О-3150-2017

249036, г. Обнинск, ул. Королева, д. 4

Grigorii V. Afonin – Cand. Sci. (Med.), senior researcher of the department of radiation and surgical treatment of thoracic region diseases, SPIN: 9039-6110, AuthorID: 896307, ResearcherID: О-3150-2017

4 Korolev str., Obninsk 249036

https://orcid.org/0000-0002-4304-0139

Усачев

В. С.

Usachev

V. S.

Усачев Владимир Сергеевич – научный сотрудник отделения лучевого и хирургического лечения заболеваний торакальной области, SPIN: 1329-7915, AuthorID: 901529, Scopus Author ID: 57200716739

249036, г. Обнинск, ул. Королева, д. 4

Vladimir S. Usachev – researcher of the department of radiation and surgical treatment of thoracic region diseases, SPIN: 1329-7915, AuthorID: 901529, Scopus Author ID: 57200716739

4 Korolev str., Obninsk 249036

https://orcid.org/0000-0003-0406-0046

Кудрявцев

Д. Д.

Kudryavtsev

D. D.

Кудрявцев Дмитрий Дмитриевич – научный сотрудник отделения лучевого и хирургического лечения заболеваний торакальной области, SPIN: 1680-5735, AuthorID: 969421, ResearcherID: C-8505-2018, Scopus Author ID: 57202291709

249036, г. Обнинск, ул. Королева, д. 4

Dmitriy D. Kudryavtsev – researcher of the department of radiation and surgical treatment of thoracic region diseases, SPIN: 1680-5735, AuthorID: 969421, ResearcherID: C-8505-2018, Scopus Author ID: 57202291709

4 Korolev str., Obninsk 249036

https://orcid.org/0000-0002-3573-6996

Колобаев

И. В.

Kolobaev

I. V.

Колобаев Илья Владимирович – к.м.н., заведующий отделением лучевого и хирургического лечения заболеваний торакальной области, SPIN: 1382-5529, AuthorID: 878091

249036, г. Обнинск, ул. Королева, д. 4

Ilya V. Kolobaev – Cand. Sci. (Med.), head of the department of radiation and surgical treatment of thoracic region diseases, SPIN: 1382-5529, AuthorID: 878091

4 Korolev str., Obninsk 249036

https://orcid.org/0000-0001-7689-6032

Иванов

С. А.

Ivanov

S. A.

Иванов Сергей Анатольевич – д.м.н., профессор РАН, директор , SPIN: 4264-5167, AuthorID: 710405, ResearcherID: N-8221-2017, Scopus Author ID: 16070399200

249036, г. Обнинск, ул. Королева, д. 4

Sergei A. Ivanov – Dr. Sci. (Med.), professor of the Russian Academy of Sciences, director A. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological Center, SPIN: 4264-5167, AuthorID: 710405, ResearcherID: N-8221-2017, Scopus Author ID: 16070399200

4 Korolev str., Obninsk 249036

МРНЦ им. А. Ф. Цыба – филиал ФГБУ «НМИЦ радиологии» Минздрава РоссииРоссияA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenteRussian Federation

2021

23062021

82109123

2021

Смоленов Е.И., Афонин Г.В., Усачев В.С., Кудрявцев Д.Д., Колобаев И.В., Иванов С.А.

Smolenov E.I., Afonin G.V., Usachev V.S., Kudryavtsev D.D., Kolobaev I.V., Ivanov S.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.rpmj.ru/rpmj/article/view/727

На сегодняшний день рак легкого является одной из самых актуальных проблем онкологии в мире. В лечении неоперабельных форм немелкоклеточного рака легкого оптимальным методом остается химиолучевое лечение. Одной из новых возможностей лекарственной терапии, которая показывает улучшение показателя общей выживаемости при раке легкого, является терапия ингибиторами контрольных точек иммунного ответа – моноклональных антител, которые блокируют иммуносупрессивные белки, повышающие регуляцию на поверхности Т-клеток и улучшающие собственную иммунную систему пациента для реагирования на опухолевые клетки. В 2019 г. в клиническую практику внедрен препарат дурвалумаб для лечения пациентов с неоперабельной III стадией немелкоклеточного рака легкого (НМРЛ), достигших, по крайней мере, стабилизации заболевания после проведенного химиолучевого лечения. В данной работе представлены исследования, изучающие проведение лучевой терапии с различными группами препаратов, оказывающих влияние на контрольные точки иммунного ответа.

Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC). Nowadays, immune response checkpoint inhibitors (monoclonal antibodies) are actively introduced into clinical practice which demonstrated significant improvements in the overall survival for patients with unresectable NSCLC. These drugs block programmed cell death protein (PD‑1) and programmed cell death ligand 1 (PD-L1) that increases regulation on the surface of T-cells and improves the patient's immune system respond to tumor cells. In 2019, durvalumab was introduced into clinical practice for the treatment of patients with unresectable NSCLC (stage III) after chemoradiotherapy. In our study, we’ve summarizes studies investigated the feasibility and safety of radiotherapy with immunotherapy for locally advanced lung cancer.

немелкоклеточный рак легкогоНМРЛлучевая терапияхимиотерапияиммунотерапиямоноклональные антителаингибиторы PDхимиолучевая терапия

non-small cell lung cancerNSCLCradiotherapychemotherapyimmunotherapymonoclonal antibodyPD inhibitorchemoradiotherapy

References1

Состояние онкологической помощи населению России в 2019 г. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой, М.: 2020, 236 с. Доступно по: https://glavonco.ru/cancer_register/Помощь%202019.pdf

The state of cancer care in Russia in 2019 Ed. by A.D.Kaprin, V.V.Starinsky, G.V.Petrova, M.: 2020, 236 p. (In Russian). Available at: https://glavonco.ru/cancer_register/Помощь%202019.pdf

Рагулин Ю.А. Сочетание иммунотерапии и лучевой терапии при немелкоклеточном раке легкого. Онкология. Журнал им. П.А.Герцена. 2018;7(5):90–96. https://doi.org/10.17116/onkolog2018705190

Ragulin Yu.A. The combination of immunotherapy and radiation therapy for non-small cell lung cancer. Oncology. P.A.Herzen Journal. 2018;7(5):90–96. (In Russian). https://doi.org/10.17116/onkolog2018705190

Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И.Переводчиковой, В.А.Горбуновой. M.: Практическая медицина, 2015, 686 с.

Guidelines for chemotherapy of tumor diseases. Ed. by N. I. Perevodchikova, V. A. Gorbunova. M.: Practical medicine, 2015, 686 p. (In Russian).

NCCN.org. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for non-small cell lung cancer V.4.2021. © National Comprehensive Cancer Network, Inc., 2021. Доступно по: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

NCCN.org. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for non-small cell lung cancer V.4.2021. © National Comprehensive Cancer Network, Inc., 2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Рагулин Ю.А., Смоленов Е.И., Усачев В.С., Афонин Г.В. Таргетная терапия местно-распространенного немелкоклеточного рака легкого с EGFR – мутацией. Онкология. Журнал им. П.А.Герцена. 2016;5(2):48–53. https://doi.org/10.17116/onkolog20165248-53

Ragulin YuA, Smolenov EI, Usachev VS, Afonin GV. Targeted therapy for locally advanced non-small-cell lung cancer with EGFR mutation. Oncology. P.A.Herzen Journal. 2016;5(2):48–53. (In Russian). https://doi.org/10.17116/onkolog20165248-53

Злокачественное новообразование бронхов и легкого. Ассоциация онкологов России. Клинические рекомендации. Под ред. А.Д. Каприна. М.: 2020, 90 с.

Malignant neoplasm of the bronchi and lung. Association of Oncologists of Russia. Clinical recommendations. Ed. by A.D.Kaprin. M.: 2020, 90 p. (In Russian).

Родионов Е.О., Миллер С.В., Тузиков С.А., Ефтеев Л.А., Маркович В.А., Миллер Д.С. Иммунотерапия рецидивного немелкоклеточного рака легкого в первой линии. Медицинский Совет. 2019;(19):132–136. https://doi.org/10.21518/2079-701X-2019-19-132-136

Rodionov EO, Miller SV, Tuzikov SA, Efteev LA, Markovich VA, Miller DS. Immunotherapy in first-line treatment of recurrent non-small cell lung cancer. Meditsinskiy sovet = Medical Council. 2019;(19):132–136. (In Russian). https://doi.org/10.21518/2079-701X-2019-19-132-136

Болотина Л.В., Каприн А.Д. Иммуноонкология: новые горизонты лекарственной терапии солидных опухолей. Онкология. Журнал им. П.А.Герцена. 2017;6(5):74–80. https://doi.org/10.17116/onkolog20176574-80

Bolotina LV, Kaprin AD. Immuno-oncology: new possibilities of drug therapy for solid tumours. Oncology. P.A.Herzen Journal. 2017;6(5):7480. (In Russian). https://doi.org/10.17116/onkolog20176574-80

Сакаева Д.Д., Ручкин В.В., Гончарова О.В., Аббасова Р.Р., Муфазалов Ф.Ф. Дурвалумаб в терапии местно-распространенного немелкоклеточного рака легкого после химиолучевого лечения в реальной практике. Современная онкология. 2019;21(3);21–25. https://doi.org/10.26442/18151434.2019.3.190679

Sakaeva DD, Ruchkin VV, Goncharova ОV, Аbbasova RR, Mufazalov FF. Durvalumab in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy in a real practice. Journal of Modern Oncology. 2019;21(3);21–25. (In Russian). https://doi.org/10.26442/18151434.2019.3.190679

Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27. https://doi.org/10.1159/000386035

Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer. 1971 Jul;28(1):89–98. https://doi.org/10.1002/1097-0142(197107)28:13.0.co;2-q

Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, et al. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Apr 10;34(11):1223–1230. https://doi.org/10.1200/JCO.2015.63.0970

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002 Nov;3(11):991–998. https://doi.org/10.1038/ni1102-991

Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015 Jun 18;6:e1792. https://doi.org/10.1038/cddis.2015.162

Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013 Apr;13(4):227–242. https://doi.org/10.1038/nri3405

Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975 Feb;53(1):27–42. https://doi.org/10.1038/icb.1975.3

Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009 May;229(1):12–26. https://doi.org/10.1111/j.1600-065X.2009.00770.x

Лактионов К.К., Саранцева К.А., Бредер В.В., Окружнова М.А., Перегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2016;(3):17–24. https://doi.org/10.18027/2224-5057-2016-3-17-24

Laktionov KK, Sarantseva KA, Breder VV, Okruzhnova MA, Peregudova MV. Immunotherapy for non-small cell lung cancer treatment. Malignant tumours. 2016;(3):17-24. (In Russian). https://doi.org/10.18027/2224-5057-2016-3-17-24

Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug;224:166–182. https://doi.org/10.1111/j.1600-065X.2008.00662.x

Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099–8103. https://doi.org/10.1073/pnas.94.15.8099

Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010 Aug;140(2):377–386. https://doi.org/10.1016/j.jtcvs.2009.12.054

Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010 Feb 20;28(6):928–935. https://doi.org/10.1200/JCO.2009.25.0928

O'Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD002140. https://doi.org/10.1002/14651858.CD002140.pub3

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181–2190. https://doi.org/10.1200/JCO.2009.26.2543

Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187–199. https://doi.org/10.1016/S1470-2045(14)71207-0

Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1325–1331. https://doi.org/10.1016/j.ijrobp.2012.11.011

Hepel JT, Leonard KL, Safran H, Ng T, Taber A, Khurshid H, et al. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1021–1027. https://doi.org/10.1016/j.ijrobp.2016.08.032

Higgins KA, Pillai RN, Chen Z, Tian S, Zhang C, Patel P, et al. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. J Thorac Oncol. 2017 Nov;12(11):1687–1695. https://doi.org/10.1016/j.jtho.2017.07.036

Kumar S, Feddock J, Li X, Shearer AJ, Hall L, Shelton BJ, et al. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):652–659. https://doi.org/10.1016/j.ijrobp.2017.07.036

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1352–1358. https://doi.org/10.1016/j.ijrobp.2009.07.1751

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010 Mar 17;303(11):1070–1076. https://doi.org/10.1001/jama.2010.261

Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016 Feb;40(1):25–37. https://doi.org/10.1016/j.currproblcancer.2015.10.001

Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer. 2016 Feb;40(1):10–24. https://doi.org/10.1016/j.currproblcancer.2015.10.003

Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med. 2016 Mar;4(6):118. https://doi.org/10.21037/atm.2016.01.32

Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862–870. https://doi.org/10.1016/j.ijrobp.2003.09.012

Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008 Aug;22(9):1064–1084.

Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1685–1693. https://doi.org/10.1097/JTO.0000000000000686

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 Feb;124(2):687–695. https://doi.org/10.1172/JCI67313

Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Jul;12(7):1085–1097. https://doi.org/10.1016/j.jtho.2017.04.014

Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016 Jun 16;1(9):e87415. https://doi.org/10.1172/jci.insight.87415

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014 Oct 1;74(19):5458–5468. https://doi.org/10.1158/0008-5472.CAN-14-1258

Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clin Cancer Res. 2017 Sep 15;23(18):5514–5526. https://doi.org/10.1158/1078-0432.CCR-16-1673

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373–377. https://doi.org/10.1038/nature14292

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 Nov 3;375(18):1749– 1755. https://doi.org/10.1056/NEJMoa1609214

Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020 Feb;15(2):288–293. https://doi.org/10.1016/j.jtho.2019.10.002

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul;18(7):895–903. https://doi.org/10.1016/S1470-2045(17)30380-7

Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020 Oct 1;126(19):4353–4361. https://doi.org/10.1002/cncr.33083

Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa S-I, et al. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer. Anticancer Res. 2017 Sep;37(9):5199–5205. https://doi.org/10.21873/anticanres.11943

Kataoka Y, Ebi N, Fujimoto D, Hara S, Hirano K, Narabayashi T, et al. Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study. Ann Oncol. 2017 Jun 1;28(6):1402. https://doi.org/10.1093/annonc/mdx114

Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):344–351. https://doi.org/10.1016/j.ijrobp.2017.02.003

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan;15(1):59–68. https://doi.org/10.1016/S1470-2045(13)70510-2

Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015 Jun;26(6):1134–1142. https://doi.org/10.1093/annonc/mdv104

Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for nonsmall cell lung cancer. Eur J Cancer. 2015 Nov;51(16):2321–2329. https://doi.org/10.1016/j.ejca.2015.07.035

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011 Nov 1;17(21):6847–6857. https://doi.org/10.1158/1078-0432.CCR-11-1385

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generateabscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795–803. https://doi.org/10.1016/S1470-2045(15)00054-6

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795–803. https://doi.org/10.1016/S1470-2045(15)00054-6

Fujimoto D, Uehara K, Sato Y, Sakanoue I, Ito M, Teraoka S, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep. 2017 Sep 12;7(1):11373. https://doi.org/10.1038/s41598-017-11949-9

Hecht M, Büttner-Herold M, Erlenbach-Wünsch K, Haderlein M, Croner R, Grützmann R, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016 Sep;65:52–60. https://doi.org/10.1016/j.ejca.2016.06.015

Lim SH, Hong M, Ahn S, Choi Y-L, Kim K-M, Oh D, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer. 2016 Jan;52:1–9. https://doi.org/10.1016/j.ejca.2015.09.019

Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, et al. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res. 2017 Apr;6(2):148–158. https://doi.org/10.21037/tlcr.2017.03.06

The authors declare that there are no conflicts of interest present.